In a prespecified secondary analysis of the phase 3 S1826 trial in stage III-IV classic Hodgkin lymphoma, nivolumab-AVD vs BV-AVD improved 3-year PFS in EBV-positive (91% vs 70%; HR 0.30; 522 with known EBV status) and non-NS histology (86% vs 63%; HR 0.33) subgroups.
Secondary analysisn = 970
Ahmed et al. Impact of EBV status and histology on patient outcomes with nivolumab-AVD vs BV-AVD in advanced classic Hodgkin lymphoma (S1826)